AN2 Therapeutics Overview
Valuation check: ANTX's P/E ratio is -5.5, below the sector sector average of 33.83.
Get informed when a big investor buys or sells
+ Follow-5.50
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, ANTX shows a P/E ratio of -5.5. That is below the sector sector average of 33.83. Scroll down for historical charts and peer comparison views.
The its sector sector average P/E ratio is about 33.83. AN2 Therapeutics is at -5.5, which is lower that average. That is roughly 116.3% below the sector mean. Use the comparison chart on this page to see how ANTX stacks up against individual peers as well.
Investors watch ANTX's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. AN2 Therapeutics's latest reading is -5.5. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has AN2 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -5.5) with ownership activity and broader fundamentals.
